Diseases /
Non-Small Cell Lung Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy. [1]
Non-small cell lung carcinomas most frequently harbor alterations in TP53, KRAS, EGFR, CDKN2A, and STK11 [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in non-small cell lung carcinoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for non-small cell lung carcinoma, 25 are FDA-approved in at least one setting and 29 have NCCN guidelines in at least one setting [3].
Ado-Trastuzumab Emtansine +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN. |
Afatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Single agent (FDA, NCCN), or may be considered in combination with cetuximab after progression on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy (NCCN). |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Single agent, or may be considered in combination with cetuximab after progression on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NICE, SMC) |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Relapse (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ALK rearrangements who relapsed on crizotinib. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ROS1 rearrangements who relapsed on crizotinib. |
Alectinib +
Amivantamab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Indicated for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, with progression on or after platinum-based chemotherapy. |
Atezolizumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved for the first-line treatment of adult patients with metastatic NSCLC with high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK alterations. |
Brigatinib +
Cabozantinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended by NCCN under Category 2A |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (MCG) |
Capmatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for adult patients with metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended by NCCN for patients with high-level MET amplification. |
Cemiplimab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: For high expression of PD-L1 (Tumor Proportion Score >= 50%, clone 22C3) in the absence of EGFR/ALK/ROS1 (FDA/NCCN) and RET/BRAF V600E/MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy. |
Ceritinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Approved by FDA for patients with ALK-positive metastatic NSCLC. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended by NCCN as first line of therapy |
Crizotinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Approved by FDA for patients with ALK-positive or ROS1-positive metastatic NSCLC. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Approved by FDA for patients with ALK-positive or ROS1-positive metastatic NSCLC. Recommended by NCCN as a preferred agent for first-line therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended by NCCN under Category 2A for patients with high-level MET amplification or MET exon 14 skipping mutations. |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (MCG) |
| Note: ROS1 D2033N and ROS1 G2032R have been identified as resistance mutations in patients treated with crizotinib. For more information, see Gainor, J., et al., 2017 (PMID: 29333528). |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (MCG) |
| Note: Secondary mutations associated with ALK TKI therapy may arise in the kinase domain, leading to acquired resistance. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (BNF) |
| Note: Secondary mutations associated with ALK TKI therapy may arise in the kinase domain, leading to acquired resistance. |
Dacomitinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ROS1 rearrangements who relapsed on crizotinib. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Relapse (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ALK rearrangements who relapsed on crizotinib. |
Dasatinib +
Entrectinib +
Disease is predicted to be sensitive: -
Erlotinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Single agent or in combination with ramucirumab (FDA, NCCN), or in combination with bevacizumab (NCCN, non-squamous only). |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Single agent, or in combination with bevacizumab (non-squamous only) or ramucirumab. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): First Line of Therapy (NICE, SMC), Metastatic (NICE, BNF, SMC) |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ROS1 rearrangements who relapsed on crizotinib |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Relapse (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ALK rearrangements who relapsed on crizotinib. |
Fam-Trastuzumab Deruxtecan +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN. |
Gefitinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): First Line of Therapy (NICE), Metastatic (NICE, SMC) |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ROS1 rearrangements who relapsed on crizotinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Relapse (NCCN) |
| Note: Not recommend by NCCN in subsequent lines of therapy, in patients with ALK rearrangements who relapsed on crizotinib. |
Lorlatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved by FDA for patients with ALK-positive, metastatic NSCLC. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended by NCCN as subsequent line of therapy after progression on crizotinib or ceritinib |
Osimertinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Indicated for metastatic, EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Also NCCN-recommended as adjuvant therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Preferred first-line therapy, per NCCN. Also approved as adjuvant therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Preferred first-line therapy, per NCCN. Also recommended as adjuvant therapy. |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (MCG) |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (MCG) |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (MCG) |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Clinical Setting(s): Metastatic (MCG) |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
Pembrolizumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: For low expression of PD-L1 (Tumor Proportion Score >= 1% and <50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy (for patients with contraindications to combination chemotherapy, per NCCN), or as subsequent line with disease progression during or following appropriate systemic chemotherapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: For high expression of PD-L1 (Tumor Proportion Score >= 50%, clone 22C3) in the absence of EGFR & ALK (FDA/NCCN) and ROS1, RET, BRAF V600E, and MET Exon 14 Skipping (NCCN) mutations: recommended as a single agent for first-line therapy, or as subsequent line with disease progression during or following appropriate systemic chemotherapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (FDA) |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Second Line of Therapy (NICE, SMC) |
| Note: Pembrolizumab is indicated as subsequent therapy for patients with NSCLC expressing CD274 (programmed death ligand 1 (PD-L1)), and whose disease has progressed on or after platinum-containing chemotherapy. An improved overall response rate was observed in CD274 (PD-L1) positive tumors. |
Pralsetinib +
Selpercatinib +
Sotorasib +
Disease is predicted to be sensitive: -
Tepotinib +
Disease is predicted to be sensitive: -
Vandetanib +
Disease is predicted to be sensitive: -
Vemurafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, single-agent vemurafenib is an option if the combination of dabrafenib + trametinib is not tolerated. |
Afatinib + Capmatinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Cetuximab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, may be considered after progression on on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
Afatinib + Crizotinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN) |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Dabrafenib + Trametinib +
Disease is predicted to be sensitive: -
Ipilimumab + Nivolumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must not match any of the following: Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (FDA) |
| Note: Approved as first-line treatment for patients with metastatic NSCLC whose tumors express PD-L1(≥1%), with no EGFR or ALK genomic tumor aberrations. |
Ipilimumab + Nivolumab + Platinum Doublet Therapy +
Disease is predicted to be sensitive: -
Clinical Trials
There are 1117 clinical trials for non-small cell lung carcinoma, of which 841 are open and 276 are completed or closed. Of the trials that contain non-small cell lung carcinoma as an inclusion criterion, 14 are early phase 1 (9 open), 310 are phase 1 (210 open), 205 are phase 1/phase 2 (165 open), 416 are phase 2 (320 open), 10 are phase 2/phase 3 (8 open), 131 are phase 3 (108 open), 11 are phase 4 (8 open), and 20 are no phase specified (13 open).
EGFR, PD-L1, and KRAS are the most frequent gene inclusion criteria for non-small cell lung carcinoma clinical trials [3].
Pembrolizumab, nivolumab, and pemetrexed are the most common interventions in non-small cell lung carcinoma clinical trials.
Significant Genes in Non-Small Cell Lung Carcinoma
ABL1 +
ABL1 is altered in 1.74% of non-small cell lung carcinoma patients [2].
ABL1 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ABL2 +
ABL2 is altered in 0.47% of non-small cell lung carcinoma patients [2].
ABL2 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ACVR1B +
ACVR1B is altered in 1.66% of non-small cell lung carcinoma patients [2].
ACVR1B is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
AKT1 +
AKT1 is altered in 0.91% of non-small cell lung carcinoma patients [2].
AKT1 is an inclusion eligibility criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain AKT1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 4 are phase 2 (3 open) [3].
AKT2 +
AKT2 is altered in 1.84% of non-small cell lung carcinoma patients [2].
AKT2 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain AKT2 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (1 open) [3].
AKT3 +
AKT3 is altered in 1.51% of non-small cell lung carcinoma patients [2].
AKT3 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain AKT3 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (1 open) [3].
ALK +
ALK is altered in 5.44% of non-small cell lung carcinoma patients [2].
ALK is an inclusion eligibility criterion in 78 clinical trials for non-small cell lung carcinoma, of which 54 are open and 24 are closed. Of the trials that contain ALK status and non-small cell lung carcinoma as inclusion criteria, 2 are early phase 1 (1 open), 20 are phase 1 (14 open), 11 are phase 1/phase 2 (8 open), 28 are phase 2 (18 open), 1 is phase 2/phase 3 (1 open), 11 are phase 3 (10 open), 2 are phase 4 (2 open), and 3 are no phase specified (0 open) [3].
Ceritinib, crizotinib, alectinib, brigatinib, lorlatinib, and pembrolizumab have evidence of efficacy in patients with ALK mutation in non-small cell lung carcinoma [3].
APC +
APC is altered in 5.39% of non-small cell lung carcinoma patients [2].
APC is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ARAF +
ARAF is altered in 1.87% of non-small cell lung carcinoma patients [2].
ARAF is an inclusion eligibility criterion in 8 clinical trials for non-small cell lung carcinoma, of which 7 are open and 1 is closed. Of the trials that contain ARAF status and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (6 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
ARID1A +
ARID1A is altered in 7.88% of non-small cell lung carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
ASS1 +
ASS1 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASS1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ASXL1 +
ASXL1 is altered in 3.32% of non-small cell lung carcinoma patients [2].
ASXL1 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ATM +
ATM is altered in 7.14% of non-small cell lung carcinoma patients [2].
ATM is an inclusion eligibility criterion in 9 clinical trials for non-small cell lung carcinoma, of which 7 are open and 2 are closed. Of the trials that contain ATM status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
ATR +
ATR is altered in 3.72% of non-small cell lung carcinoma patients [2].
ATR is an inclusion eligibility criterion in 6 clinical trials for non-small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain ATR status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
ATRX +
ATRX is altered in 5.83% of non-small cell lung carcinoma patients [2].
ATRX is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATRX status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
AXL +
AXL is altered in 1.67% of non-small cell lung carcinoma patients [2].
AXL is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AXL status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 1.91% of non-small cell lung carcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 5 clinical trials for non-small cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BARD1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
BCL2L11 +
BCL2L11 is altered in 0.34% of non-small cell lung carcinoma patients [2].
BCL2L11 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BCL2L11 status and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open) [3].
BLM +
BLM is altered in 2.02% of non-small cell lung carcinoma patients [2].
BLM is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
BRAF +
BRAF is altered in 5.15% of non-small cell lung carcinoma patients [2].
BRAF is an inclusion eligibility criterion in 37 clinical trials for non-small cell lung carcinoma, of which 27 are open and 10 are closed. Of the trials that contain BRAF status and non-small cell lung carcinoma as inclusion criteria, 17 are phase 1 (12 open), 5 are phase 1/phase 2 (4 open), and 15 are phase 2 (11 open) [3].
Dabrafenib, trametinib, dasatinib, pembrolizumab, and vemurafenib have evidence of efficacy in patients with BRAF mutation in non-small cell lung carcinoma [3].
BRCA1 +
BRCA1 is altered in 3.53% of non-small cell lung carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 10 clinical trials for non-small cell lung carcinoma, of which 8 are open and 2 are closed. Of the trials that contain BRCA1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
BRCA2 +
BRCA2 is altered in 4.54% of non-small cell lung carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 10 clinical trials for non-small cell lung carcinoma, of which 8 are open and 2 are closed. Of the trials that contain BRCA2 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
BRIP1 +
BRIP1 is altered in 2.38% of non-small cell lung carcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 5 clinical trials for non-small cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRIP1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
C11ORF30 +
C11orf30 is altered in 0.49% of non-small cell lung carcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain C11orf30 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
CBL +
CBL is altered in 1.81% of non-small cell lung carcinoma patients [2].
CBL is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CBL status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
CCND1 +
CCND1 is altered in 2.54% of non-small cell lung carcinoma patients [2].
CCND1 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
CDK12 +
CDK12 is altered in 2.45% of non-small cell lung carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 7 clinical trials for non-small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain CDK12 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
CDK4 +
CDK4 is altered in 3.49% of non-small cell lung carcinoma patients [2].
CDK4 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
CDK6 +
CDK6 is altered in 1.03% of non-small cell lung carcinoma patients [2].
CDK6 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CDKN1A +
CDKN1A is altered in 0.44% of non-small cell lung carcinoma patients [2].
CDKN1A is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CDKN1B +
CDKN1B is altered in 1.24% of non-small cell lung carcinoma patients [2].
CDKN1B is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CDKN2A +
CDKN2A is altered in 13.2% of non-small cell lung carcinoma patients [2].
CDKN2A is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDKN2A status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].
CHD4 +
CHD4 is altered in 2.22% of non-small cell lung carcinoma patients [2].
CHD4 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CHEK1 +
CHEK1 is altered in 0.84% of non-small cell lung carcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
CHEK2 +
CHEK2 is altered in 1.57% of non-small cell lung carcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain CHEK2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
CRKL +
CRKL is altered in 0.9% of non-small cell lung carcinoma patients [2].
CRKL is an inclusion eligibility criterion in 8 clinical trials for non-small cell lung carcinoma, of which 7 are open and 1 is closed. Of the trials that contain CRKL status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].
CSF1R +
CSF1R is altered in 1.74% of non-small cell lung carcinoma patients [2].
CSF1R is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CTNNB1 +
CTNNB1 is altered in 3.05% of non-small cell lung carcinoma patients [2].
CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CYLD +
CYLD is altered in 1.81% of non-small cell lung carcinoma patients [2].
CYLD is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DDR2 +
DDR2 is altered in 2.83% of non-small cell lung carcinoma patients [2].
DDR2 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain DDR2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
DICER1 +
DICER1 is altered in 2.76% of non-small cell lung carcinoma patients [2].
DICER1 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DNMT3A +
DNMT3A is altered in 3.82% of non-small cell lung carcinoma patients [2].
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
EGFR +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients [2].
EGFR is an inclusion eligibility criterion in 247 clinical trials for non-small cell lung carcinoma, of which 182 are open and 65 are closed. Of the trials that contain EGFR status and non-small cell lung carcinoma as inclusion criteria, 2 are early phase 1 (1 open), 54 are phase 1 (36 open), 37 are phase 1/phase 2 (28 open), 109 are phase 2 (82 open), 5 are phase 2/phase 3 (4 open), 29 are phase 3 (24 open), 4 are phase 4 (2 open), and 7 are no phase specified (5 open) [3].
Afatinib, osimertinib, gefitinib, erlotinib, dacomitinib, capmatinib, crizotinib, amivantamab, cetuximab, and pembrolizumab have evidence of efficacy in patients with EGFR mutation in non-small cell lung carcinoma [3].
EPCAM +
EPCAM is altered in 0.56% of non-small cell lung carcinoma patients [2].
EPCAM is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
EPHA2 +
EPHA2 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 3.97% of non-small cell lung carcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 34 clinical trials for non-small cell lung carcinoma, of which 25 are open and 9 are closed. Of the trials that contain ERBB2 status and non-small cell lung carcinoma as inclusion criteria, 8 are phase 1 (4 open), 7 are phase 1/phase 2 (5 open), and 19 are phase 2 (16 open) [3].
Ado-trastuzumab emtansine and fam-trastuzumab deruxtecan have evidence of efficacy in patients with ERBB2 mutation in non-small cell lung carcinoma [3].
ERBB3 +
ERBB3 is altered in 1.93% of non-small cell lung carcinoma patients [2].
ERBB3 is an inclusion eligibility criterion in 5 clinical trials for non-small cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
ERBB4 +
ERBB4 is altered in 4.18% of non-small cell lung carcinoma patients [2].
ERBB4 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB4 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
ERCC2 +
ERCC2 is altered in 1.82% of non-small cell lung carcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC3 +
ERCC3 is altered in 1.47% of non-small cell lung carcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC4 +
ERCC4 is altered in 1.88% of non-small cell lung carcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC4 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC5 +
ERCC5 is altered in 2.46% of non-small cell lung carcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC5 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC6 +
ERCC6 is altered in 1.04% of non-small cell lung carcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC6 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
EXO1 +
EXO1 is altered in 3.87% of non-small cell lung carcinoma patients [2].
EXO1 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is altered in 0.96% of non-small cell lung carcinoma patients [2].
EZH2 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
FANCA +
FANCA is altered in 3.0% of non-small cell lung carcinoma patients [2].
FANCA is an inclusion eligibility criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FANCA status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
FANCB +
FANCB is altered in 2.7% of non-small cell lung carcinoma patients [2].
FANCB is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCB status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCC +
FANCC is altered in 0.9% of non-small cell lung carcinoma patients [2].
FANCC is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCC status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCD2 +
FANCD2 is altered in 6.32% of non-small cell lung carcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCD2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCE +
FANCE is altered in 1.29% of non-small cell lung carcinoma patients [2].
FANCE is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCE status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCF +
FANCF is altered in 1.05% of non-small cell lung carcinoma patients [2].
FANCF is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCF status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCG +
FANCG is altered in 1.28% of non-small cell lung carcinoma patients [2].
FANCG is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCG status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCI +
FANCI is altered in 3.31% of non-small cell lung carcinoma patients [2].
FANCI is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCI status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCL +
FANCL is altered in 1.49% of non-small cell lung carcinoma patients [2].
FANCL is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCL status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FANCM +
FANCM is altered in 6.75% of non-small cell lung carcinoma patients [2].
FANCM is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCM status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
FGFR1 +
FGFR1 is altered in 3.54% of non-small cell lung carcinoma patients [2].
FGFR1 is an inclusion eligibility criterion in 9 clinical trials for non-small cell lung carcinoma, of which 7 are open and 2 are closed. Of the trials that contain FGFR1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 7 are phase 2 (6 open) [3].
FGFR2 +
FGFR2 is altered in 1.17% of non-small cell lung carcinoma patients [2].
FGFR2 is an inclusion eligibility criterion in 9 clinical trials for non-small cell lung carcinoma, of which 7 are open and 2 are closed. Of the trials that contain FGFR2 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 7 are phase 2 (6 open) [3].
FGFR3 +
FGFR3 is altered in 1.48% of non-small cell lung carcinoma patients [2].
FGFR3 is an inclusion eligibility criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FGFR3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (4 open) [3].
FGFR4 +
FGFR4 is altered in 1.93% of non-small cell lung carcinoma patients [2].
FGFR4 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FH +
FH is altered in 1.33% of non-small cell lung carcinoma patients [2].
FH is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FH status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
FLT1 +
FLT1 is altered in 4.22% of non-small cell lung carcinoma patients [2].
FLT1 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FLT1 status and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (3 open) [3].
FLT3 +
FLT3 is altered in 2.19% of non-small cell lung carcinoma patients [2].
FLT3 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is altered in 3.96% of non-small cell lung carcinoma patients [2].
FLT4 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FLT4 status and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (3 open) [3].
FRK +
FRK is altered in 0.08% of non-small cell lung carcinoma patients [2].
FRK is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
GATA3 +
GATA3 is altered in 2.11% of non-small cell lung carcinoma patients [2].
GATA3 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
GRB2 +
GRB2 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GRB2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
HDAC1 +
HDAC1 is altered in 0.38% of non-small cell lung carcinoma patients [2].
HDAC1 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
HGF +
HGF is altered in 4.52% of non-small cell lung carcinoma patients [2].
HGF is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
HRAS +
HRAS is altered in 0.5% of non-small cell lung carcinoma patients [2].
HRAS is an inclusion eligibility criterion in 15 clinical trials for non-small cell lung carcinoma, of which 11 are open and 4 are closed. Of the trials that contain HRAS status and non-small cell lung carcinoma as inclusion criteria, 10 are phase 1 (8 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].
IDH1 +
IDH1 is altered in 0.89% of non-small cell lung carcinoma patients [2].
IDH1 is an inclusion eligibility criterion in 2 clinical trials for non-small cell lung carcinoma, of which 0 are open and 2 are closed. Of the trials that contain IDH1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open) [3].
IDH2 +
IDH2 is altered in 0.55% of non-small cell lung carcinoma patients [2].
IDH2 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KDM6A +
KDM6A is altered in 2.61% of non-small cell lung carcinoma patients [2].
KDM6A is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KDR +
KDR is altered in 3.82% of non-small cell lung carcinoma patients [2].
KDR is an inclusion eligibility criterion in 6 clinical trials for non-small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain KDR status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [3].
KEAP1 +
KEAP1 is altered in 14.08% of non-small cell lung carcinoma patients [2].
KEAP1 is an inclusion eligibility criterion in 4 clinical trials for non-small cell lung carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KEAP1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
KIT +
KIT is altered in 2.09% of non-small cell lung carcinoma patients [2].
KIT is an inclusion eligibility criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain KIT status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 4 are phase 2 (4 open) [3].
KMT2D +
KMT2D is altered in 10.11% of non-small cell lung carcinoma patients [2].
KMT2D is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KRAS +
KRAS is altered in 29.61% of non-small cell lung carcinoma patients [2].
KRAS is an inclusion eligibility criterion in 73 clinical trials for non-small cell lung carcinoma, of which 57 are open and 16 are closed. Of the trials that contain KRAS status and non-small cell lung carcinoma as inclusion criteria, 34 are phase 1 (26 open), 15 are phase 1/phase 2 (13 open), 19 are phase 2 (13 open), and 5 are phase 3 (5 open) [3].
Sotorasib has evidence of efficacy in patients with KRAS mutation in non-small cell lung carcinoma [3].
MAGI2 +
MAGI2 is altered in 0.98% of non-small cell lung carcinoma patients [2].
MAGI2 is an inclusion eligibility criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MAP2K1 +
MAP2K1 is altered in 0.97% of non-small cell lung carcinoma patients [2].
MAP2K1 is an inclusion eligibility criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MAP2K1 status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
MAP2K2 +
MAP2K2 is altered in 0.7% of non-small cell lung carcinoma patients [2].
MAP2K2 is an inclusion eligibility criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MAP2K2 status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].